Granulocyte death mediated by specific antibodies in intravenous immunoglobulin (IVIG).
Sign Up to like & getrecommendations! Published in 2019 at "Pharmacological research"
DOI: 10.1016/j.phrs.2019.02.007
Abstract: Granulocytes are key effector cells of the innate immune system that cause substantial by-stander tissue damage in a broad range of inflammatory disorders. Specific antibodies with the potential to regulate granulocyte survival are present in… read more here.
Keywords: specific antibodies; granulocyte death; intravenous immunoglobulin; immunoglobulin ivig ... See more keywords
Pompholyx as a side effect of intravenous immunoglobulin (IVIg)
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Case Reports"
DOI: 10.1136/bcr-2022-248772
Abstract: Intravenous immunoglobulin (IVIg) is increasingly used across multiple specialties for the treatment of inflammatory and autoimmune diseases. Cutaneous reactions to IVIg are generally minor. Pompholyx is a common eruption of small vesicles on the palms,… read more here.
Keywords: intravenous immunoglobulin; immunoglobulin ivig; side effect;
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/10781552221118529
Abstract: Introduction The efficacy of immune checkpoint inhibitors (ICIs) against malignant melanoma and numerously solid tumors has been demonstrated in several clinical studies. The incidence of immune-related adverse effects (irAEs) has increased after the rapidly expanding… read more here.
Keywords: encephalitis; immunoglobulin ivig; nivolumab ipilimumab; intravenous immunoglobulin ... See more keywords
Intravenous Immunoglobulin (IVIG) for Patients with Severe Neurotoxicity Associated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Sign Up to like & getrecommendations! Published in 2025 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms26083904
Abstract: Severe immune effector cell-associated neurotoxicity syndrome (ICANS) occurs in about 30% of all patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel). There are currently limited treatment strategies other than the… read more here.
Keywords: intravenous immunoglobulin; therapy; immunoglobulin ivig; severe icans ... See more keywords